STC 15
Alternative Names: STC-15Latest Information Update: 28 Nov 2025
At a glance
- Originator Evotec SE; Storm Therapeutics
- Class 2 ring heterocyclic compounds; Amides; Amines; Antineoplastics; Cyclobutanes; Indoles; Ketones; Pyridines; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action METTL3 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer
- No development reported Acute myeloid leukaemia; Haematological malignancies; Solid tumours
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Capsule)
- 29 Aug 2025 Chemical structure information added.
- 27 May 2025 STORM Therapeutics enters a collaboration and supply agreement with Coherus Bioscience for a phase I/II trial for STC 15